"Effect of Terminalia Chebula in treatment of melasma"

Evaluating the effect of Myrobalan (Terminalia Chebula.) cream, 5% compared to hydroquinone cream, 2% in the treatment of melasma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110310006026N10

Enrollment

Registered

2019-09-29

Start date

2019-09-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: Intervention group: 5% myrobalan cream which rub a thin layer of medicine every night and wash face in the morning. Intervention 2: Control group: 2% hydroquinone cream which rub a thi

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Women in the 18-55 age range with melasma

Exclusion criteria

Exclusion criteria: Pregnancy, lactation, antiepileptic drugs and spironolactone Thyroid disorders, polycystic ovary syndrome, anti-smear drug use during last 6 months, Use of oral and phototoxic contraceptives since last month, sensitivity to hydroquinone or Terminalia Chebula

Design outcomes

Primary

Measure	Time frame
Melanin. Timepoint: At the beginning of treatment and at the end of weeks 4, 8 and 12. Method of measurement: Modified Melasma Area and Severity Index (MMASI).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Dabaghzadeh

Kerman University of Medical Sciences

fatemeh.dabaghzadeh@gmail.com+98 34 3132 5034

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026